review · International Journal of Nanomedicine
Conventional wound healing treatments face major challenges, particularly in chronic conditions where rapid drug degradation, poor localised availability, and premature drug release reduce their therapeutic impact. Nanostructured lipid carriers present a drug delivery alternative capable of protecting delicate active compounds from environmental breakdown while ensuring sustained, controlled release. These carrier systems can be manufactured using accessible techniques, including emulsification, pressure-based processing, solvent methods, and phase inversion. Requiring minimal material compositions, they support the delivery of single or combined pharmaceutical agents. Evidence across laboratory testing, animal models, and clinical studies demonstrates that nanostructured lipid carriers improve treatment performance by reducing particle size, increasing drug solubility, enhancing bioavailability, and maintaining effective drug concentrations directly at the wound site over extended periods.
Chronic wounds are difficult to treat because conventional medicines break down rapidly or release immediately before healing can occur. Nanostructured lipid carriers solve this by shielding therapeutic molecules and releasing them gradually. This approach keeps active drugs working at the wound site for longer, supporting more dependable therapies that improve healing outcomes and reduce complications associated with long-term wound care.
This technology applies to chronic wound treatment and advanced drug delivery, targeting pharmaceutical developers and wound-care product manufacturers. Because preparation involves established techniques such as emulsification and phase inversion, and existing evidence already spans laboratory, animal, and clinical studies, the approach appears relatively mature and well positioned for applied formulation development and translation into commercial wound-healing products.
AI-generated from the published abstract. Always read the original work before citing.
The current treatments for wound healing still exhibit drawbacks due to limited availability at the action sites, susceptibility to degradation, and immediate drug release, all of which are detrimental in chronic conditions. Nano-modification strategies, offering various advantages that can enhance the physicochemical properties of drugs, have been employed in efforts to maximize the efficacy of wound healing medications. Nowadays, nanostructured lipid carriers (NLCs) provide drug delivery capabilities that can safeguard active compounds from environmental influences and enable controlled release profiles. Consequently, NLCs are considered an alternative therapy to address the challenges encountered in wound treatment. This review delves into the application of NLCs in drug delivery for wound healing, encompassing discussions on their composition, preparation methods, and their impact on treatment effectiveness. The modification of drugs into the NLC model can be facilitated using relatively straightforward technologies such as pressure-based processes, emulsification techniques, solvent utilization methods, or phase inversion. Moreover, NLC production with minimal material compositions can accommodate both single and combination drug delivery. Through in vitro, in vivo, and clinical studies, it has been substantiated that NLCs can enhance the therapeutic potential of various drug types in wound healing treatments. NLCs enhance efficacy by reducing the active substance particle size, increasing solubility and bioavailability, and prolonging drug release, ensuring sustained dosage at the wound site for chronic wounds. In summary, NLCs represent an effective nanocarrier system for optimizing the bioavailability of active pharmacological ingredients in the context of wound healing.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.2147/ijn.s478964
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
